[Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
OBJECTIVE
To evaluate modifications on lipid profile, fibrinogen and platelet aggregation induced by etofibrate.


METHODS
Twenty-one adult patients were studied. They all had primary hyperlipidemia and had already been on the AHA step I diet and placebo. Etofibrate (500mg/day) was administered for 60 days in the active phase, when lipid parameters, fibrinogen and platelet aggregation were measured.


RESULTS
The % significant reductions were: total cholesterol (-9.50%), LDL-cholesterol (-7.88%), triglycerides (-19.07%), total cholesterol/HDL-cholesterol(-11.90%), LDL-cholesterol/HDL-cholesterol (-10.20%), fibrinogen (-12.79%), platelet aggregation with adrenaline (-24.02%), with ADP 1 mumol (-30.13%), and ADP 3 mumol (-24.51%).


CONCLUSIONS
The beneficial effects of etofibrate were observed not only on the lipid profile but also on the thrombogenic parameters measured by fibrinogen and platelet aggregation.
Fonseca
F A
FA
Escola Paulista de Medicina-UNIFESP, Sö Paulo.
Novazzi
J P
JP
Cendoroglo
M S
MS
Duarte
M
M
Almeida Pinto
L E
LE
Rabelo
L M
LM
da Rocha Martinez
T L
TL
D000328:Adult; D002995:Clofibric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D005340:Fibrinogen / Q000032:analysis / Q000187:drug effects*; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; C009746:etofibrate; D002995:Clofibric Acid; D005340:Fibrinogen
Modificações lipídicas do fibrinogênio e da agregação plaqutária induzidas pelo etofibrato.